Advertisement

Treatment of Pediatric Migraine

Opinion statement

The diagnosis of migraine in the pediatric population is increasing as providers are becoming more familiar with recognizing the condition. Over-the-counter and migraine-specific treatment, once considered off-label, have proven to be effective, especially if given at the early onset of head pain. Mild to severe cases of migraine should be treated with nonsteroidal anti-inflammatory drugs (NSAIDs), with triptans used alone or in combination in moderate to severe headaches unresponsive to over-the-counter therapy. Rescue medication including dihydroergotamine (DHE), a potent vasoconstrictor should be used for intractable migraines and is preferred in the hospital setting. Anti-emetics that have anti-dopaminergic properties can be helpful in patients with associated symptoms of nausea and vomiting along with headache, especially when used in combination therapy. Preventative treatment should be initiated early in patients with frequent headaches to improve headache outcomes and quality of life. Patients and families should be educated on non-pharmacologic management, such as lifestyle modification and avoidance of triggers, that can prevent progression and worsening of migraine.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

Fig. 1

References and Recommended Reading

    Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

    1. 1.•

      Eapen A, Sivaswamy L, et al. Management of pediatric migraine in a tertiary care versus community based emergency department: an observational pilot study. Pediatr Neurol. 2014;50(2):164–70. Describes treatments given in ED and supports use of standard treatment for migraine in the pediatric population.

    2. 2.

      Brousseau DC, Duffy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med. 2004;43(2):256–62.

    3. 3.••

      International Headache Society, The International Classification of Headache Disorders, Third Edition (beta version). Cephalalgia. 2013;33(9):629–808. The most recent criteria for the diagnosis of headache disorders.

    4. 4.

      Lewis DW, Ashwal S, Hershey A, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents. Neurology. 2004;63:2215–24.

    5. 5.

      Siberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754–62.

    6. 6.

      O’Brien HL, Kabbouche MA, Hershey AD. Treating pediatric migraine: an expert opinion. Expert Opin Pharmacother. 2012;13(7):959–66.

    7. 7.

      O’Brien HL, Kabbouche MA, Hershey AD. Treatment of acute migraine in the pediatric population. Curr Treat Options Neurol. 2010;12(3):178–85.

    8. 8.••

      Powers SW, Kashikar-Zuck SM, Hershey AD, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA. 2013;310(24):2622–30. Describes recent study of evidence supporting behavioral treatment with medication for migraine in children.

    9. 9.

      Eidlitz-Markus T, Haimi-Cohen Y, Steier D, Zeharia A. Effectiveness of nonpharmacologic treatment for migraine in young children. Headache, Accepted for publication Aug 4, 2009.

    10. 10.

      Lynch-Jordan AM, Sil S, Peugh J, et al. Differential changes in functional disability and pain intensity over the course of psychological treatment for children with chronic pain. Pain 2014. Accessed September 9, 2014.

    11. 11.

      Hamalainen ML, Hoppu K, Valkeila E, Santvuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children. Neurology. 1997;48:103–7.

    12. 12.

      Lewis DW, Kellsein D, Sahl G, et al. Children’s ibuprofen suspension for the acute treatment of pediatric migraine. Headache. 2002;42(8):780–6.

    13. 13.

      McDonald SA, Hershey AD, Pearlman E, et al. Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescents. Headache. 2011;51:1374–8.

    14. 14.

      Hershey AD, Powers SW, Vockell AL, LeCates SL, Seegers A, Kabbouche MA. Development of a patient-based grading scale for PedMIDAS. Cephalagia. 2004;24(10):844–9.

    15. 15.

      Gillies D, Sills M, Forsythe I. Pizotifen (Sanomigran) in childhood migraine. A double-blind controlled trial. Eur Neurol. 1986;25:32–5.

    16. 16.

      Battistella PA, Ruffilli R, Gernetti R, et al. A placebo-controlled crossover trial using trazodone in pediatric migraine. Headache. 1993;33:36–9.

    17. 17.

      Ferreira J, Garcia N, Pedreira L. Topiramate in pediatric and adolescent migraine patients: a retrospective analysis. Headache. 2002;42:453.

    18. 18.

      Hershey AD, Powers SW, Vockell AL, et al. Effectiveness of topiramate in the prevention of childhood headaches. Headache. 2002;42(8):965–73.

    19. 19.

      Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache. 2004;44:238–43.

    20. 20.

      Pakalnis A, Kring D. Zonisamide prophylaxis in refractory pediatric headache. Headache. 2006;46(5):804–7.

    21. 21.

      Belman AL, Milazo M, Savatic M. Gabapentin for migraine prophylaxis in children. Ann Neurol. 2001;50(Suppl1):S109.

    22. 22.

      Roa BS, Das DG, Taraknath VR, Sarma Y. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India. 2000;28:223–6.

    23. 23.

      Ludvigsson J. Propranolol used in prophylaxis of migraine in children. Acta Neurol Scand. 1974;50:109–15.

    24. 24.

      Forsythe WI, Gillies D, Sills MA. Propranolol (Inderal) in the treatment of childhood migraine. Dev Med Child Neurol. 1984;26:737–41.

    25. 25.

      Olness K, MacDonald JT, Uden DL. Comparison of self-hypnosis and propranolol in the treatment of juvenile classic migraine. Pediatrics. 1987;79:593–7.

    26. 26.

      Sillanpää M. Clonidine prophylaxis of childhood migraine and other vascular headache. Headache. 1977;17:28–31.

    27. 27.

      Sills M, Congdon P, Forsythe I. Clonidine and childhood migraine: a pilot and double-blind study. Dev Med Child Neurol. 1982;24(6):837–41.

    28. 28.

      Sorge F, Marano E. Flunarizine v. placebo in childhood migraine. Cephalalgia. 1985;5(Suppl2):145–8.

    29. 29.

      Sorge F, De Simone R, Marano E, Nolano M, Orefice G, Carrieri P. Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study. Cephalalgia. 1988;8:1–6.

    30. 30.

      Noronha MJ. Double-blind randomised cross-over trial of timolol in migraine prophylaxis in children. Cephalalgia. 1985;5 Suppl 3:174–5.

    31. 31.

      Slater SK, Nelson TD, Kabbouche MA, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Headache. 2011;45(8):983–91.

    32. 32.

      Hershey AD, Powers SW, Vockel AL, Lecates SL, Ellinor SL, Segers A, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache. 2007;47(1):73–80.

    33. 33.

      Bruijin J, Duivenvoorden H, Passchier J, Locher H, Dijkstra N, Arts WF. Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia. 2010;30(12):1426–34.

    34. 34.

      MacLennan SC et al. High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol. 2008;23(11):1300–4.

    35. 35.

      Chan VW, McCabe EJ, MacGregor DL. Botox treatment for migraine and chronic daily headache in adolescents. J Neurosci Nurs. 2009;41(5):235–43.

    36. 36.

      Ahmed K, Oas KH, Mack KJ, et al. Experience with botulinum toxin type A in medically intractable pediatric chronic daily headache. Pediatr Neurol. 2010;5:316–9.

    37. 37.

      Kabbouche MA, O’Brien HL, Hershey AD. OnabotulinumtoxinA in pediatric chronic daily headache. Curr Neurol Neurosci Rep. 2012;12(2):114–7.

    38. 38.

      Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. Ann Emerg Med. 2004;43(2):256–62.

    39. 39.

      Kabbouche MA, Powers SW, Vockell AB, et al. Inpatient management of pediatric patients for intractable headache and status migrainosus. Headache. 2003;42:551.

    40. 40.

      Trottier ED, Bailey B, Lucas N, Lortie A. Prochlorperazine in children with migraine: a look at its effectiveness and rate of akathisia. Am J Emerg Med. 2012;30(3):456–63.

    41. 41.

      Lipton RB, Golstein J, Baggish JS, et al. Aspirin is efficacious for the treatment of acute migraine. Headache. 2005;45:283–92.

    42. 42.

      Matchar DB, Young WB, Rosenberg JH, et al. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks. Neurology 2000; 54; www.aan.com/public/practiceguidelines/03.pdf. Accessed 31 Oct 2009.

    43. 43.

      Ahya SN, Flood K, Paranjothi S, editors. The Washington manual of medical therapeutics. 3rd ed. Philadelphia: Lippincott; 2001.

    44. 44.

      Larkin G. Intravenous ketorolac vs. intravenous prochlorperazine for the treatment of migraine headache. Acad Emerg Med. 1999;6:668–70.

    45. 45.

      Schilling A et al. Acetaminophen: old drug, new warnings. Cleve Clin J Med. 2010;77(1):19–27.

    46. 46.

      Winner P. Triptans for migraine management in adolescents. Headache. 2002;42:675–9.

    47. 47.

      http://www.healthcentral.com/migraine/c/202/73741/axert-adolescents. Accessed 1 Nov 2009.

    48. 48.

      Winner P, Lewis D, Visser H, et al. Rizatriptan 5mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache. 2002;42:49–55.

    49. 49.

      Ho TW, Peralman E, Lewis D, et al. Efficacy and tolerability of rizatriptan I pediatric migraineurs; results from a randomized, double-blind, placebo controlled trial using a novel adaptive enrichment design. Cephalalgia. 2012;32(10):750–65.

    50. 50.

      Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics. 2000;106:989–97.

    51. 51.

      Rothner AD, Winner P, Nett R, et al. Long-term tolerability of sumatriptan nasal spray for adolescent migraine: results of an open-label study. Clin Ther. 2001;22:1533–46.

    52. 52.

      Lewis DW, Winner P, Hershey AD, Wasiewski WW. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics. 2007;120:390–6.

    53. 53.

      Linder SL, Mathew NT, Cady RK, Finlayson G, Ishkanian G, Lewis DW. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache. 2008;48:1326–36.

    54. 54.

      Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007;297:1443–54.

    55. 55.

      Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. Headache. 1994;34:578–80.

    56. 56.

      Richer L, Graham L, Klassen T, Rowe B. Emergency department management of acute migraine in children in Canada: a practice variation study. Headache. 2007;47(5):703–10.

    57. 57.

      Coppola M, Yearly DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med. 1995;26(5):541–6.

    58. 58.

      Peroutka SJ. Dopamine and migraine. Neurology. 1997;49:650–6.

    59. 59.

      Kabbouche MA, Vockell AL, LeCates SL, et al. Tolerability and effectiveness of prochlorperazine for intractable migraine in children. Pediatrics. 2001;107(4):E62.

    60. 60.

      Kabbouche MA, Powers SW, Hershey AD, et al. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. Headache. 2009;49:106–9.

    61. 61.

      Yonker ME. How I do it Reference for Acute Migraine Treatment in Children. www.ahs.org. Accessed 1 Nov 2009.

    62. 62.

      Schwatz TH, Kapritskiy VV, Sohn RS. Intravenous valproate sodium in the treatment of daily headache. Headache. 2002;42(6):519–22.

    63. 63.

      Hershey AD, Powers SW, Winner P, Kabbouche MA. Pediatric headache in clinical practice. Chichester: Wiley Blackwell; 2009.

    64. 64.

      Kacperski J, Hershey AD. Preventive drugs in childhood and adolescent migraine. Curr Pain Headache Rep. 2014;18(6):422–7.

    65. 65.

      El-Chammas K, Keyes J, Thompson N, Vijayakumar J, Becher D, Jackson JL. Pharmacologic treatment of pediatric headaches. JAMA Pediatr. 2013;167(3):250–8.

    66. 66.

      Lipton RB, Silberstein SD, Saper JR, Bigal ME, Goadsby PJ. Why headache treatment fails. Neurology. 2003;60:1064–70.

    67. 67.

      Hershey AD, Powers SW, Coffey CS, Eklund DD, Chamberlin LA, Korbee LL. Childhood and Adolescent Migraine Prevention (CHAMP) Study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in prevention of childhood and adolescent migraine. Headache. 2013;53:799–816.

    68. 68.

      Hershey AD, Powers SW, Bentii AL, Degrauw TJ. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache. 2000;40:539–49.

    69. 69.

      Winner P, Pearlman EM, Linder SL. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45:1304–12.

    70. 70.

      Lewis D, Winner P, Saper J, Ness S, Polverejan E, Wang S, et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics. 2009;123(3):924–34.

    71. 71.

      Fallah R, Divanizadeh MS, Karimi M, Mirouliaei M, Shamszadeh A. Topiramate and propranolol for prophylaxis of migraine. Indian J Pediatr. 2013.

    72. 72.

      Bidabadi E, Mashouf M. A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients. Paediatr Drugs. 2010;54(3):269–75.

    73. 73.

      Unalp A, Uran N, Ozturk A. Comparison of the effectiveness of topiramate and sodium valproate in pediatric migraine. J Child Neurol. 2008;23:1377–81.

    74. 74.

      Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001;41(2):119–28.

    75. 75.

      Hershey AD, Powers SW, Winner P, Kabbouche MA. Pediatric headaches in clinical practice. 1st ed. Oxford: Wiley; 2009.

    76. 76.

      Termine C, Ozge A, Antonaci F, Natriashvili S, Guidetti V, Wober-Bingol C. Overview of diagnosis and management of paediatric headache. Part II: therapeutic management. J Headache Pain. 2011;12(1):25–34.

    77. 77.

      Ahmed K, Oas KH, Mack KJ, Garza I. Experience with botulinum toxin A in medically intractable pediatric chronic daily headache. Pediatr Neurol. 2010;43(5):316–9.

    78. 78.

      Slater SK, Nelson TD, Kabbouche MA, Lecates SL, Horn P, Segers A, et al. A randomized, double-blinded, placebo-controlled, crossover, add on study of coenzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2010;31(8):897–905.

    79. 79.

      Condo M, Posar A, Arbizzani A, Parmeggiani A. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain. 2009;10(5):361–5.

    80. 80.

      O’Brien HL, Hershey AD. Vitamins and paediatric migraine: riboflavin as a preventative medication. Cephalalgia. 2010;30(12):1417–8.

    Download references

    Compliance with Ethics Guidelines

    Conflict of Interest

    Hope L. O’Brien declares the receipt of research funding from Labry Biologics.

    Marielle A. Kabbouche is a co-investigator for GlaxoSmithKline and Merck, and a consultant for Allergan.

    Joanne Kacperski declares no conflict of interest.

    Andrew D. Hershey has received research funding from GlaxoSmithKline and Merck and is a member of the Advisory Board for MAP Pharma.

    Human and Animal Rights and Informed Consent

    This article does not contain any studies with human or animal subjects performed by any of the authors.

    Author information

    Correspondence to Hope L. O’Brien MD.

    Additional information

    This article is part of the Topical Collection on Headache

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    O’Brien, H.L., Kabbouche, M.A., Kacperski, J. et al. Treatment of Pediatric Migraine. Curr Treat Options Neurol 17, 1 (2015) doi:10.1007/s11940-014-0326-1

    Download citation

    Keywords

    • Pediatric migraine
    • Primary headache
    • Treatment
    • NSAIDs
    • Triptans
    • Dopamine antagonists
    • DHE
    • Nutraceuticals
    • Headache prevention
    • Chronic migraine